β-Cell rejuvenation with thiazolidinediones

American Journal of Medicine

Volumn 115, Issue 8 SUPPL. 1, 2003, Pages 20-23

  Bell, David S H ^a  

^a UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; C PEPTIDE; GLIBENCLAMIDE; INSULIN; METFORMIN; PLACEBO; PROINSULIN; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; TROGLITAZONE;

CELL FUNCTION; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFECT; HUMAN; HYPOGLYCEMIA; INSULIN RESISTANCE; LIVER; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; REJUVENATION; SIDE EFFECT; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0346219298     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2003.08.010     Document Type: Conference Paper

References (18)

1. Pimenta W., Korytkowski M., Mitrakou A., et al. Pancreatic beta-cell dysfunction as the primary genetic lesion in NIDDM evidence from studies in normal glucose-tolerant individuals with a first-degree NIDDM relative . JAMA. 273:1995;1855-1861.
2. Lebovitz H.E. Insulin secretagogues old and new . Diabetes Reviews. 7:1999;l39-l53.
3. Wallace T.M., Matthews D.R. Poor glycaemic control in type 2 diabetes a conspiracy of disease, suboptimal therapy and attitude . Q J Med. 93:2000;369-374.
4. Bell D.S.H., Ovalle F. Tissue triglyceride levels in type 2 diabetes and the role of thiazolidinediones in reversing the effects of tissue hypertriglyceridemia review of the evidence in animals and humans . Endocr Pract. 7:2001;135-138.
5. Cnop M., Grupping A., Hoorens A., et al. Endocytosis of low-density lipoprotein by human pancreatic beta cells and uptake in lipid-storing vesicles, which increase with age. Am J Pathol. 156:2000;237-244.
6. Meyer C.J., Bogardus C., Mott D.M., Pratley R.E. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest. 104:1999;787-797.
7. Shimabukuro M., Ohneda M., Lee Y., Unger R.H. Role of nitric oxide in obesity-induced β cell disease. J Clin Invest. 100:1997;290-295.
8. Unger R.H. How obesity causes diabetes in Zucker diabetic fatty rats. Trends Endocrinol Metab. 8:1997;276-282.
9. Gremlich S., Bonny C., Waeber G., Thorens B. Fatty acids decrease IDX-1 expression in rat pancreatic islets and reduce GLUT2, glucokinase, insulin, and somatostatin levels. J Biol Chem. 272:1997;30261-30269.
10. Butler A.E., Janson J., Bonner-Weir S., et al. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes. 52:2003;102-110.
11. Mayerson A.B., Hundal R.S., Dufour S., et al. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes. 51:2002;797-802.
12. Lister C.A., Moore G.B.T., Piercy V., et al. Rosiglitazone, but not metformin or glibenclamide, improves glycaemic control and increases islet insulin content. [abstract] Diabetologia. 42:(suppl 1):1999;A150.
13. Finegood D.T., McArthur M.D., Kojwang D., et al. β-cell mass dynamics in Zucker diabetic fatty rats rosiglitazone prevents the rise in net cell death . Diabetes. 50:2001;1021-1029.
14. Ward W.K., LaCava E.C., Paquette T.L., et al. Disproportionate elevation of immunoreactive proinsulin in type 2 (non-insulin-dependent) diabetes mellitus and in experimental insulin resistance. Diabetologia. 20:1987;698-702.
15. Porter L.E., Freed M.I., Jones N.P., Biswas N. Rosiglitazone improves β-cell function as measured by proinsulin/insulin ratio in patients with type 2 diabetes. [abstract] Diabetes. 49:(suppl 1):2000;A122.
16. Ovalle F., Bell D.S.H. Clinical evidence of thiazolidinedione-induced improvement of pancreatic β-cell function in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 4:2002;56-59.
17. Bell D.S.H., Ovalle F. Long-term efficacy of triple oral therapy for type 2 diabetes mellitus. Endocr Pract. 8:2002;271-275.
18. Buchanan T.A., Xiang A.H., Peters R.K., et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes. 51:2002;2796-2803.